MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
Full FDA approval covers proteinuria reduction in FSGS without nephrotic syndrome, a defined clinical subset differentiated ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
Investor's Business Daily on MSN
Four biotech stocks near buy points as earnings season kicks in
Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...
Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...
Investor's Business Daily on MSN
Stock market leaders emerge in IBD 50, rise in volume after follow-through day
Stock market leaders have emerged in the IBD 50 after the S&P 500's follow-through day, many with strong up/down volume ratios.
Find the latest TG Therapeutics, Inc. (TGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results